We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Genisphere Awarded Patent for Whole Transcriptome Next Generation Sequencing
News

Genisphere Awarded Patent for Whole Transcriptome Next Generation Sequencing

Genisphere Awarded Patent for Whole Transcriptome Next Generation Sequencing
News

Genisphere Awarded Patent for Whole Transcriptome Next Generation Sequencing

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Genisphere Awarded Patent for Whole Transcriptome Next Generation Sequencing"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Genisphere LLC has reported that it has been granted a US patent for a novel strand-specific library preparation method for next generation sequencing based on its proven RNA amplification technology.

The new patented process enables amplification and library preparation from clinically relevant RNA samples, adapts easily to a variety of sequencing instruments and systems, and reduces the time required for sample preparation by eliminating labor intensive steps.

Genisphere's RNA amplification technology employs a robust whole-transcriptome amplification process that has been successfully integrated into several assay systems. In 2008, Genisphere's amplification technology was incorporated into the Pathwork Diagnostics Tissue of Origin Test (now offered by Response Genetics), which was cleared by the FDA in 2010. In 2011, the latest version of the company's amplification technology, trademarked Sensation®, was licensed to Affymetrix for microarray applications.

"Genisphere's technology for whole transcriptome amplification is a dynamic commonality among our diverse corporate initiatives, which include targeted therapeutics, clinical diagnostics, and life science", said Bob Getts, Genisphere's Chief Science Officer. "We are pleased to offer these methods to our collaborators and partners who are interested in broadening their translational research initiatives in the areas of new drug discovery, diagnostic assay development, and moving next generation sequencing from the research lab to the clinic. We also see this as an excellent tool to complement our 3DNA nanoparticle technology used for targeted drug delivery since it will help to uncover those molecules that will be ideal targets for companion diagnostics based on next generation sequencing."

Advertisement